“This financing demonstrates our continuous progress and strong confidence from our current investors. Their support allows us to continue the development and puts us in a stronger position ahead of our next financing round for clinical studies,” says Felipe Velasquez, CEO of Omnio, in a press release.
Omnio raises €2.9m for chronic wound therapy
Swedish biotech company Omnio has secured €2.9 million from existing investors and shareholders. The funding will be used to advance its plasminogen-based biological therapy for chronic wounds into first-in-human clinical studies.
Advertisement
BREAKING